ERG Transcriptional Networks in Primary Acute Leukemia Cells Implicate a Role for ERG in Deregulated Kinase Signaling

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bock, Juliane ^a   Mochmann, Liliana H ^a   Schlee, Cornelia ^a   Farhadi Sartangi, Nasrin ^a   Göllner, Stefanie ^b   Müller Tidow, Carsten ^b   Baldus, Claudia D ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DOVITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; SORAFENIB; TRANSCRIPTION FACTOR ERG; WNT PROTEIN;

ACUTE LEUKEMIA; ARTICLE; CANCER RESISTANCE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISHEVELED ASSOCIATED ACTIVATOR OF MORPHOGENESIS 1 GENE; DRUG SENSITIVITY; GENE; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUMB GENE; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

COMPUTATIONAL BIOLOGY; FLOW CYTOMETRY; FLUORESCENT DYES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; JURKAT CELLS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS;

EID: 84871878659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052872     Document Type: Article

References (39)

1. Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, et al. (2008) The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nat Immunol 9(7): 810-819.
2. Taoudi S, Bee T, Hilton A, Knezevic K, Scott J, et al. (2011) ERG dependence distinguishes developmental control of hematopoietic stem cell maintenance from hematopoietic specification. Genes Dev. 25(3): 251-262.
3. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, et al. (2008) A causal role for ERG in neoplastic transformation of prostate epithelium. PNAS 105(6): 2105-2110.
4. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310(5748): 644-648.
5. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, et al. (1994) A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature Genetics 6(2): 146-151.
6. Kong XT, Ida K, Ichikawa H, Shimizu K, Ohki M, et al. (1997) Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16; 21)(p11; q22) and identification of a novel transcript. Blood 90(3): 1192-1199.
7. Eid MA, Attia M, Abdou S, Elahwal L, Farrag W, et al. (2010) BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. International Journal of Laboratory Hematology 32(2): 197-205.
8. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K, et al. (2005) Overexpression of the ETS-Related Gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B Study. Journal of Clinical Oncology 23(36): 9234-9242.
9. Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, et al. (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. Journal of Clinical Oncology 27(30): 5031-5038.
10. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, et al. (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. Journal of Clinical Oncology 24(29): 4714-20.
11. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, et al. (2009) ERG is a megakaryocytic oncogene. Cancer Research 69(11): 4665-4673.
12. Thoms JA, Birger Y, Foster S, Knezevic K, Kirschenbaum Y, et al. (2011) ERG promotes T-acute lymphoblastic leukemia and is transcriptionally regulated in leukemic cells by a stem cell enhancer. Blood 117(26): 7079-7089.
13. Tsuzuki S, Taguchi O, Seto M, (2012) Promotion and maintenance of leukemia by ERG. Blood 117(26): 7079-89.
14. Mochmann LH, Bock J, Ortiz-Tanchez J, Schlee C, Bohne A, et al. (2011) Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG. Oncogene 30(17): 2044-2056.
15. Weinmann AS, Bartley SM, Zhang T, Zhang MQ, Farnham PJ, et al. (2001) Use of Chromatin Immunoprecipitation To Clone Novel E2F Target Promoters. Molecular and Cellular Biology 21(20): 6820-6832.
16. Müller-Tidow C, Klein H, Hascher A, Isken F, Tickenbrock L, et al. (2010) Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 116(18): 3564-3571.
17. Hoemme C, Peerzada A, Behre G, Wang Y, McClelland M, et al. (2008) Chromatin modifications induced by PML-RAR α repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood 111(5): 2887-2895.
18. Huang DW, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Research 37(1): 1-13.
19. Zambelli F, Pesole G, Pavesi G (2009) Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Research 37, 247-252.
20. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, et al. (2010) FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Research 70(17): 6735-6745.
21. Birdsey GM, Dryden NH, Amsellem V, Gebhardt F, Sahnan K, et al. (2008) Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood 111(7): 3498-3506.
22. Xin L, Teitell MA, Lawson DA, Kwon A, Mellinghoff IK, et al. (2006) Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. PNAS 103(20): 7789-7794.
23. Ouchi N, Asaumi Y, Ohashi K, Higuchi A, Sono-Romanelli S, et al. (2010) DIP2A Functions as a FSTL1 Receptor. Journal of Biological Chemistry 285(10): 7127-7134.
24. Narita N, Tanemura A, Murali R, Scolyer RA, Huang S, et al. (2009) Functional RET G691S Polymorphism in Cutaneous Malignant Melanoma. Oncogene 28(34): 3058-3068.
25. Muellner MK, Uras IZ, Gapp BV, Kerzendorfer C, Smida M, et al. (2011) A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol. 7(11): 787-793.
26. Law AJ, Wang Y, Sei Y, Donnell PO, Piantadosi P, et al. (2012) Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. PNAS 109(30): 12165-12170 4.
27. Porstmann T, Griffiths B, Chung Y, Delpuech O, Griffiths JR, et al. (2005) PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24(43): 6465-6481.
28. Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, et al. (2012) Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells. International Journal of Cancer 131(3): 582-590.
29. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, et al. (2009) ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. PNAS 106(30): 12465-12470.
30. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics 41(5): 619-624.
31. Zhu X, Ma Y, Liu D (2010) Novel agents and regimens for acute myeloid leukemia. Journal of Hematology and Oncology 3, 1-10.
32. Ravandi F, Cortes JE, Jones D, Faderl S, Garcia-Manero G, et al. (2010) Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. Journal of Clinical Oncology 28(11): 1856-1862.
33. Kim KB, Chesney J, Robinson D, Gardner H, Shi MM, et al. (2011) Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma. Clinical Cancer Research 17(23): 7451-7461.
34. Hart AH, Reventar R, Bernstein A, (2000) Genetic analysis of ETS genes in C. elegans. Oncogene 19(55): 6400-6408.
35. Oikawa T, (2004) ETS transcription factors: possible targets for cancer therapy. Cancer Science (8): 626-633.
36. Pereira JK, Traina F, Machado-Neto JA, Duarte Ada S, Lopes MR, et al. (2012) Distinct expression profiles of MSI2 and NUMB genes in myelodysplastic syndromes and acute myeloid leukemia patients. Leukemia Research 36(10): 1300-1303.
37. Engelman JA, Luo J, Cantley LC, (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews (8): 606-619.
38. Vu C, Fruman DA, (2010) Target of rapamycin signaling in leukemia and lymphoma. Clinical Cancer Research 16(22): 5374-5380.
39. Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Mathews R, et al. (2011) Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. International Journal of Oncology 39(1): 111-119.